Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 543 of 5804
-
Promising combo therapy for brain lining cancer shows hope in new trial
Disease control Recruiting nowIntrathecal chemotherapy is one of the mainstay treatment options for leptomeningeal metastases. Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patient…
Phase: NA • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New CAR t therapy aims to tackle tough leukemia
Disease control Recruiting nowThe purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThe study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma
Phase: PHASE1, PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Inhaled virus takes on lung tumors in new trial
Disease control Recruiting nowThe Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is admi…
Phase: PHASE1, PHASE2 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a lung drug save kidneys in liver patients?
Disease control OngoingPatients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death. The goal of this clinical trial is to test whether the administration of low doses of ambr…
Phase: PHASE2 • Sponsor: Noorik Biopharmaceuticals AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cocktail targets HER2-Positive bile duct cancer in small trial
Disease control OngoingThis is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as first-line treatment for cholangiocarcinoma and gallb…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for hodgkin lymphoma: targeted drug combo shows promise in early trial
Disease control Recruiting nowThe purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (AD…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can this drug fully heal the gut in Crohn's?
Disease control OngoingThe purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Phase: PHASE3 • Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to stall returning prostate cancer
Disease control OngoingThe purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abirater…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug could help teens with rare heart disease
Disease control OngoingThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Hope for rare Muscle-Weakening disease: new drug trial targets Antibody-Negative patients
Disease control OngoingThe primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). The study consists of a Part A where participant…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could your own fat cells heal a damaged brain?
Disease control Recruiting nowThe global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflamma…
Phase: PHASE2 • Sponsor: Hope Biosciences LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Gut bacteria pill could boost stomach cancer treatment
Disease control Recruiting nowThis is a randomized non-comparative, multicenter phase II study in patients with PD-L1 PD-L1 combined positive score (CPS) ≥5 advanced gastric cancer to evaluate the efficacy and safety of nivolumab and FOLFOX in combination with EXL01 as first-line treatment. After signing the…
Phase: PHASE2 • Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug targets tough cancers with specific gene flaw
Disease control TerminatedGenes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. The so-called G12D mu…
Phase: PHASE1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Tailored radiation may spare neck tissues in nasopharyngeal cancer
Disease control Recruiting nowTo evaluate whether individualized elective neck irradiation for nasopharyngeal carcinoma based on the vertebral level of metastatic lymph nodes can reduce the incidence of radiation-related adverse effects and improve patients' quality of life,without reducing survival.
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC
-
Magic mushroom therapy targets Cancer-Related depression
Symptom relief Recruiting nowTo learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New CAR-T therapy targets Tough-to-Treat lymphomas
Disease control OngoingPhase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug vs. brain stimulation: which stops suicidal thoughts faster?
Symptom relief CompletedThis study is a multicenter, randomized, non-inferiority, parallel-group clinical trial designed to evaluate the efficacy and safety of esketamine compared with electroconvulsive therapy (ECT) in the treatment of suicidal ideation during depressive episodes in patients with mood …
Phase: NA • Sponsor: Capital Medical University • Aim: Symptom relief
Last updated Jun 26, 2026 13:46 UTC
-
Can prostate cancer patients skip hormone therapy? new trial tests SBRT alone
Disease control Recruiting nowFor this study, unfavorable intermediate risk prostate cancer patients will select whether they are to be treated with the standard of care (SOC) 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic body radiation therapy/radiosurgery (SBRT) directed to…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo aims to halt stomach cancer spread
Disease control Recruiting nowThis study is being done to answer the following question: Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs? We are doing this study because we want to find out if this approach is be…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC